Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. BETi treatment induces apoptosis of AML BPCs, reduces in vivo AML burden and ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiskus, Warren, Cai, Tianyu, DiNardo, Courtney D., Kornblau, Steven M., Borthakur, Gautam, Kadia, Tapan M., Pemmaraju, Naveen, Bose, Prithviraj, Masarova, Lucia, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Mill, Christopher P., Saenz, Dyana T., Saenz, David N., Sun, Baohua, Khoury, Joseph D., Shen, Yu, Konopleva, Marina, Bhalla, Kapil N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333829/
https://www.ncbi.nlm.nih.gov/pubmed/30647404
http://dx.doi.org/10.1038/s41408-018-0165-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333829/
https://www.ncbi.nlm.nih.gov/pubmed/30647404
http://dx.doi.org/10.1038/s41408-018-0165-5

Ejemplares similares